In addition, the authors found that FGL1 was overexpressed in some human cancers and that a high concentration of FGL1 in plasma was associated with poor prognosis and therapeutic outcomes in patients treated with anti-PD therapy; moreover, the anti-FGL1 antibody showed synergistic efficacy with anti-PD therapy [12]. The gene discussed is FGL1; the disease is cancer.